|Conference Call & Webcast|
|Monday, May 16, 2016 @ 8:30am Eastern Time|
|Replays available through May 30, 2016|
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company’s website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.